Browsing ICR Divisions by author "Wicks, Andrew"

Now showing items 1-4 of 4

    • Opinion: PARP inhibitors in cancer-what do we still need to know? 

      Wicks, AJ; Krastev, DB; Pettitt, SJ; Tutt, ANJ; Lord, CJ (The Royal Society, 2022-07-01)
      PARP inhibitors (PARPi) have been demonstrated to exhibit profound anti-tumour activity in individuals whose cancers have a defect in the homologous recombination DNA repair pathway. Here, we describe the current consensus ...

    • PARP Inhibitors - Trapped in a Toxic Love Affair. 

      Krastev, DB; Wicks, AJ; Lord, CJ
      It is often the case that when an investigational cancer drug first enters clinical development, its precise mechanism of action is unclear. This was the case for PARP inhibitors (PARPi) used to treat homologous ...

    • Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency. 

      Bajrami, I; Walker, C; Krastev, DB; Weekes, D; Song, F; et al. (NATURE PORTFOLIO, 2021-11-08)
      PARP enzymes utilise NAD+ as a co-substrate for their enzymatic activity. Inhibition of PARP1 is synthetic lethal with defects in either BRCA1 or BRCA2. In order to assess whether other genes implicated in NAD+ metabolism ...

    • The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. 

      Krastev, DB; Li, S; Sun, Y; Wicks, AJ; Hoslett, G; et al. (NATURE PORTFOLIO, 2022-01-01)
      Poly (ADP-ribose) polymerase (PARP) inhibitors elicit antitumour activity in homologous recombination-defective cancers by trapping PARP1 in a chromatin-bound state. How cells process trapped PARP1 remains unclear. Using ...